Home Nucleus Biotechnology Global Pharmacogenetic Testing in Psychiatry depression Market to 2032

Global Pharmacogenetic Testing in Psychiatry depression Market to 2032

Overview

The Global Pharmacogenetic Testing in Psychiatry depression Market is expected to reach a 2,230.70 USD Billion by 2032 and is projected to grow at a CAGR of 9.41% from 2025 to 2032.

Revenue, 2024 (USD Billion)
1,064.56
Forecast, 2032 (USD Billion)
2,230.70
CAGR, 2024 - 2032
9.41%
Report Coverage
Global

Global Pharmacogenetic Testing in Psychiatry depression Market 2018-2032 USD Billion

Global Pharmacogenetic Testing in Psychiatry depression Market, Key Findings (2025-2032)

Market Growth and Projections:

  • Market Size (2024): 1,064.56 USD Billion
  • Projected Market Size (2032): 2,230.70 USD Billion
  • CAGR (2025-2032): 9.41%

Key Findings of Global Pharmacogenetic Testing in Psychiatry depression Market

  • The Global Pharmacogenetic Testing in Psychiatry depression Market was valued at 2,230.70 USD Billion in 2024.
  • The Global Pharmacogenetic Testing in Psychiatry depression Market is likely to grow at a CAGR of 9.41% during the forecast period of 2024 to 2032.
  • In 2024, the Largest segment Saliva in Sample Segment accounted for the largest share of the market with a revenue of 791.86 USD Billion
  • The fastest growing segment CYP2C19 in Genes Segment grew Fastest with a CAGR of 12.56% during the forecast period from 2024 to 2032.

Global Pharmacogenetic Testing in Psychiatry depression Market Scope

Global Pharmacogenetic Testing in Psychiatry depression Market Segmentation & Scope
Application
  • Clinical Practice
  • Drug Development
Sample
  • Blood
  • Saliva
Drug Type
  • Vitamins/Nutraceuticals
  • Recreational Drugs
  • Over-The-Counter Medications
  • Prescription Drugs
Genes
  • COMT
  • MTHFR
  • SLC6A4
  • CYP3A4
  • HLA-A
  • HTR2A/C
  • HLA-B
  • Others
  • CYP2D6
  • CYP2C9 AND VKORC1
  • CYP2C19
Type
  • Array-Based Tests
  • Whole Genome Sequencing
End User
  • Others
  • Research Centres And Academic Institutes
  • Healthcare Providers
  • Pharmaceutical & Biotechnology Companies
Distribution Channel
  • Direct-To-Customer Services
  • Mail-Order Pharmacies
  • Hospital Pharmacies
  • Retail Pharmacies

Global Pharmacogenetic Testing in Psychiatry depression Market Data Coverage Insights

Study Period 2024-2032
Base Year 2020
Unit Revenue in USD Billion
Market Value in 2024 1,064.56 USD Billion
Market Value in 2032 2,230.70 USD Billion
CAGR (2025-2032) 9.41%
Historic Data 2016-2023
Market Segments Covered Application,Sample,Drug Type,Genes,Type,End User,Distribution Channel

Regional Insights:

  • Leading Market (2024-2032): Global, leading in terms of revenue 1,064.56 USD Billion in 2024
    • Key Country: U.S., leading in terms of revenue with value of 444.03 USD Billion in 2024.

Segments and Scope

  • Global Pharmacogenetic Testing in Psychiatry depression Market to 2032, By Application
    • Drug Development is the largest segment in Global Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a revenue of 587.00 USD Billion in the year 2024.
    • Drug Development is the Fastest growing segment in Global Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a Growth rate of 9.83 % in forecast period 2025-2032.
  • Global Pharmacogenetic Testing in Psychiatry depression Market to 2032, By Sample
    • Saliva is the largest segment in Global Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a revenue of 791.86 USD Billion in the year 2024.
    • Saliva is the Fastest growing segment in Global Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a Growth rate of 9.61 % in forecast period 2025-2032.
  • Global Pharmacogenetic Testing in Psychiatry depression Market to 2032, By Drug Type
    • Prescription Drugs is the largest segment in Global Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a revenue of 508.26 USD Billion in the year 2024.
    • Recreational Drugs is the Fastest growing segment in Global Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a Growth rate of 9.69 % in forecast period 2025-2032.
  • Global Pharmacogenetic Testing in Psychiatry depression Market to 2032, By Genes
    • CYP2C19 is the largest segment in Global Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a revenue of 249.38 USD Billion in the year 2024.
    • CYP2C19 is the Fastest growing segment in Global Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a Growth rate of 12.56 % in forecast period 2025-2032.
  • Global Pharmacogenetic Testing in Psychiatry depression Market to 2032, By Type
    • Whole Genome Sequencing is the largest segment in Global Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a revenue of 656.66 USD Billion in the year 2024.
    • Whole Genome Sequencing is the Fastest growing segment in Global Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a Growth rate of 9.75 % in forecast period 2025-2032.
  • Global Pharmacogenetic Testing in Psychiatry depression Market to 2032, By End User
    • Pharmaceutical & Biotechnology Companies is the largest segment in Global Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a revenue of 460.77 USD Billion in the year 2024.
    • Pharmaceutical & Biotechnology Companies is the Fastest growing segment in Global Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a Growth rate of 10.12 % in forecast period 2025-2032.
  • Global Pharmacogenetic Testing in Psychiatry depression Market to 2032, By Distribution Channel
    • Retail Pharmacies is the largest segment in Global Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a revenue of 474.51 USD Billion in the year 2024.
    • Retail Pharmacies is the Fastest growing segment in Global Pharmacogenetic Testing in Psychiatry depression Market to 2032 with a Growth rate of 10.10 % in forecast period 2025-2032.

Global Pharmacogenetic Testing in Psychiatry depression Market Company Share Analysis

 
Company Name Company Share Analysis
Millennium Health
Myriad Genetics, Inc.
PerkinElmer Inc.
Illumina, Inc.
Thermo Fisher Scientific Inc.
Global Pharmacogenetic Testing in Psychiatry depression Market Company Share Analysis

Global Pharmacogenetic Testing in Psychiatry depression Market Geographical Sales Distribution, 2018-2032 USD Billion

Global Pharmacogenetic Testing in Psychiatry depression Market Geographical Sales Distribution, 2018-2032 USD Billion

Global Pharmacogenetic Testing in Psychiatry depression Market Company Profiling

Global Pharmacogenetic Testing in Psychiatry depression Market Company Profiling

Industry Related Reports

Global Cell And Gene Therapy Thawing Equipment Market
Global Cleanroom Particle Counters Market
Global Clinical Laboratory Services Market
Global Circulating Tumor Cells (CTC) Liquid Biopsy Market
Global Biotechnology Market
Global Next Generation Sequencing (NGS) Market
Global Q-PCR Reagents Market
Global Rapid Diagnostic Tests (RDT) Market
Global Epigenetics Diagnostic Market
Global Gene Synthesis Market
Frequently Asked Questions
The Global Pharmacogenetic Testing in Psychiatry depression Market is segmented based on Segmentation Application,Sample,Drug Type,Genes,Type,End User,Distribution Channel.
Global Pharmacogenetic Testing in Psychiatry depression Market was valued at USD 1,064.56(Revenue in USD Billion) in 2020.
Global Pharmacogenetic Testing in Psychiatry depression Market is projected to grow at a CAGR of 9.41% during the forecast period of 2024 to 2032.
The Saliva segment is expected to dominate the Global Pharmacogenetic Testing in Psychiatry depression Market, holding a largest market share of 791.86 USD Billion in 2024

Global Pharmacogenetic Testing in Psychiatry depression Market Scope

Global Pharmacogenetic Testing in Psychiatry depression Market Segmentation & Scope
Application
  • Clinical Practice
  • Drug Development
Sample
  • Blood
  • Saliva
Drug Type
  • Vitamins/Nutraceuticals
  • Recreational Drugs
  • Over-The-Counter Medications
  • Prescription Drugs
Genes
  • COMT
  • MTHFR
  • SLC6A4
  • CYP3A4
  • HLA-A
  • HTR2A/C
  • HLA-B
  • Others
  • CYP2D6
  • CYP2C9 AND VKORC1
  • CYP2C19
Type
  • Array-Based Tests
  • Whole Genome Sequencing
End User
  • Others
  • Research Centres And Academic Institutes
  • Healthcare Providers
  • Pharmaceutical & Biotechnology Companies
Distribution Channel
  • Direct-To-Customer Services
  • Mail-Order Pharmacies
  • Hospital Pharmacies
  • Retail Pharmacies
Frequently Asked Questions
The Global Pharmacogenetic Testing in Psychiatry depression Market is segmented based on Segmentation Application,Sample,Drug Type,Genes,Type,End User,Distribution Channel.
Global Pharmacogenetic Testing in Psychiatry depression Market was valued at USD 1,064.56(Revenue in USD Billion) in 2020.
Global Pharmacogenetic Testing in Psychiatry depression Market is projected to grow at a CAGR of 9.41% during the forecast period of 2024 to 2032.
The estimated market value of the Global Pharmacogenetic Testing in Psychiatry depression Market for final year is USD 2,230.70 (USD Billion).

Global Pharmacogenetic Testing in Psychiatry depression Market Company Profiling

Global Pharmacogenetic Testing in Psychiatry depression Market Company Profiling
Frequently Asked Questions
The Global Pharmacogenetic Testing in Psychiatry depression Market is segmented based on Segmentation Application,Sample,Drug Type,Genes,Type,End User,Distribution Channel.
Global Pharmacogenetic Testing in Psychiatry depression Market was valued at USD 1,064.56(Revenue in USD Billion) in 2020.
Global Pharmacogenetic Testing in Psychiatry depression Market is projected to grow at a CAGR of 9.41% during the forecast period of 2024 to 2032.
The estimated market value of the Global Pharmacogenetic Testing in Psychiatry depression Market for final year is USD 2,230.70 (USD Billion).

Related Markets

HAVE A QUESTION?

Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.

BROWSE RELATED PAGES